Position Statements
Date Posted: 01 - January - 2019
BNF chapter:
Central nervous system
Expand/Collapse
This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis
Date Posted: 19 - July - 2022
BNF chapter:
Central nervous system
Date Posted: 01 - September - 2016
BNF chapter:
Central nervous system
Expand/Collapse
The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes
Date Posted: 14 - September - 2022
BNF chapter:
Central nervous system
Expand/Collapse
To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’
Date Posted: 01 - September - 2016
BNF chapter:
Central nervous system
Expand/Collapse
This position statement relates to the use of tapentadol MR for the following indications:
1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain